Toward Personalizing Care: Assessing Heterogeneity of Treatment Effects in Randomized Trials

Issa J Dahabreh^{1

2

3}, Dhruv S Kazi^{3

4}

Affiliations

¹ CAUSALab and Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
² Statistical Editor, JAMA.
³ Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
⁴ Harvard Medical School, Boston, Massachusetts.

Editorial

Issa J Dahabreh et al. JAMA. 2023.

. 2023 Apr 4;329(13):1063-1065.

doi: 10.1001/jama.2023.3576.

Issa J Dahabreh^{1

2

3}, Dhruv S Kazi^{3

4}

¹ CAUSALab and Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
² Statistical Editor, JAMA.
³ Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
⁴ Harvard Medical School, Boston, Massachusetts.

No abstract available

Comment on

Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19.
Goligher EC, Lawler PR, Jensen TP, Talisa V, Berry LR, Lorenzi E, McVerry BJ, Chang CH, Leifer E, Bradbury C, Berger J, Hunt BJ, Castellucci LA, Kornblith LZ, Gordon AC, McArthur C, Webb S, Hochman J, Neal MD, Zarychanski R, Berry S, Angus DC; REMAP-CAP, ATTACC, and ACTIV-4a Investigators. Goligher EC, et al. JAMA. 2023 Apr 4;329(13):1066-1077. doi: 10.1001/jama.2023.3651. JAMA. 2023. PMID: 36942550 Free PMC article.